MedTrace Logo

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

NCT00000326 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-04

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.

Conditions

  • Heroin Dependence
  • Opioid-Related Disorders

Interventions

DRUG

Heroin Dependence

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Leslie Amass, Ph.D. · University of Colorado, Denver

Study Design

Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-04-30
Primary Completion
1997-08-31
Completion
1997-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000326 on ClinicalTrials.gov